We are investigating whether the medication alpelisib is safe and effective for individuals with PIK3CA-related overgrowth spectrum. This study includes both children and adults to assess its impact on their symptoms and overall health.
Health conditions and diseases that the clinical trial is designed to study and treat.
PIK3CA-Related Overgrowth Spectrum (PROS) is a rare genetic condition characterized by abnormal growth of tissues and organs due to mutations in the PIK3CA gene. Symptoms can vary widely and may include overgrowth of limbs, facial features, and other body parts.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
